Informação sobre produto
- 14,19-Dioxa-5,7,27-triazatetracyclo[19.3.1.12,6.18,12]heptacosa-1(25),2,4,6(27),8,10,12(26),16,21,23-decaene, 11-[2-(1-pyrrolidinyl)ethoxy]-, (16E)-
- (16E)-11-[2-(1-Pyrrolidinyl)ethoxy]-14,19-dioxa-5,7,27-triazatetracyclo[19.3.1.12,6.18,12]heptacosa-1(25),2,4,6(27),8,10,12(26),16,21,23-decaene
- SB 1518
Pacritinib is a selective inhibitor of the tyrosine kinase JAK2. It has been shown to be effective against colorectal adenocarcinoma, hepatic steatosis, and minimal toxicity in preclinical trials. Pacritinib inhibits the activity of JAK2, which is an enzyme that participates in the signaling pathways of cytokines and growth factors that are involved in immune responses and cell proliferation. This drug may have potential for the treatment of infectious diseases, such as tuberculosis and leishmaniasis, as well as autoimmune diseases such as psoriasis and rheumatoid arthritis. Pacritinib is currently undergoing clinical trials for the treatment of various types of cancer, psoriasis, rheumatoid arthritis, Crohn's disease, ulcerative colitis, and other immune-mediated disorders.
Propriedades químicas
Consulta técnica sobre: 3D-MMB27279 Pacritinib
Se desejar solicitar um orçamento ou fazer uma encomenda, por favor, adicione os produtos ao seu carrinho e depois solicite um orçamento ou encomenda a partir do carrinho. É mais rápido, mais barato e poderá beneficiar-se dos descontos e outras vantagens disponíveis.
